Introduction {#Sec1}
============

Nicotine is known to produce a variety of rewarding subjective and cognitive effects (Stolerman and Jarvis [@CR76]; Levin et al. [@CR35]). In humans, some of the measurable subjective effects of nicotine include an increase in the feelings of "buzzed," "dizzy," and "stimulated" (Perkins et al. [@CR58]), while the positive cognitive effects include improvements in attention (Wesnes and Warburton [@CR82]) and memory (Rusted et al. [@CR69]; [@CR70]). The neurobiological mechanisms underlying these actions of nicotine are complex, involving not only the direct action of nicotine at receptors for acetylcholine but also changes in the release of other neurotransmitters, such as dopamine and glutamate (Watkins et al. [@CR81]). Neurochemical studies have demonstrated that, at concentrations achieved during smoking, nicotine can enhance the release and function of glutamate, through an action at presynaptic receptors (e.g., McGehee et al. [@CR42]). Enhanced release can occur in several areas of the brain, including in the ventral tegmental area and the nucleus accumbens (Schilstrom et al. [@CR74], [@CR75]; Fu et al. [@CR13]; Reid et al. [@CR62], Mansvelder and McGehee [@CR39]; Fagen et al. [@CR11]), the prefrontal cortex (Toth et al. [@CR78]; Gioanni et al. [@CR14]), and the hippocampus (Gray et al. [@CR16]; Radcliffe et al. [@CR61]).

Evidence from behavioral models also indicates a role for glutamate in the neurobiological mechanisms underlying the actions of nicotine. In rodents, it has been reported that antagonists acting at *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor sites can attenuate nicotine self-administration, the nicotine discriminative stimulus, and nicotine-enhanced brain reward function (Glick et al. [@CR15]; Blokhina et al. [@CR2]; Zakharova et al. [@CR84]; but see also Wright et al. [@CR83]; Kenny et al. [@CR29]). Receptor sites other than NMDA may also be involved in these actions of nicotine as the metabotropic GluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) has also been reported to be effective in models of self-administration (Paterson et al. [@CR57]; Paterson and Markou [@CR56]). In studies of the cognitive effects of nicotine, interactions with glutamatergic ligands have been reported in tests of working memory and visual signal detection (Levin et al. [@CR34]; May-Simera and Levin [@CR41]; Rezvani and Levin [@CR66]), and Quarta et al. ([@CR60]) have recently reported that the competitive NMDA receptor antagonist (+)3-(2-carboxypiperazin-4-propyl)-1-propenyl-1-phosphonic acid (CPP) attenuated the ability of nicotine to improve response accuracy in a five-choice serial reaction time task. In a spatial navigation task performed by aged rats, CPP also blocked a beneficial effect of nicotine on acquisition, while [d]{.smallcaps}-cycloserine enhanced the effect of a subthreshold dose of nicotine (Riekkinen and Riekkinen [@CR67]). In mice, Ciamei et al. ([@CR6]) showed that the NMDA antagonist dizocilpine could block the positive effects of nicotine on memory consolidation, at a dose not producing impairment per se.

Few studies have examined the involvement of glutamate in the actions of nicotine or smoking in humans. Knott et al. ([@CR30]) found some evidence for nicotine--glutamate interactions on both subjective and EEG measures in volunteers given nicotine gum, although effects varied with smoking status. Recently, we demonstrated the involvement of the NMDA receptor in the effects of smoking (Jackson et al. [@CR25]). In this study, the NMDA antagonist memantine was effective in blocking the subjective but not the cognitive enhancing effects of smoking. In contrast, a low dose (10 mg) of the nicotinic-receptor antagonist mecamylamine reduced the smoking-induced improvement in attentional performance only. These results suggested that there is a dissociation in the role of glutamate in the subjective and cognitive effects of smoking. It has been argued however that although memantine acts primarily at the ion channel of the NMDA receptor, during the physiological release of glutamate, it dissociates rapidly from the channel, to allow a normal receptor response to glutamate (Parsons et al. [@CR53]; [@CR54]). As this putative special action of memantine complicates the interpretation of results aimed at clarifying the role of glutamate, we carried out a further investigation, using a different modulator of NMDA receptor function.

Endogenous glycine acts as a "co-agonist" at a distinct site on the NMDA receptor, known as the GlycineB site, and in doing so enhances the action of glutamate. Although the GlycineB site was once thought to be saturated in vivo, there is now consensus that it is not (Danysz and Parsons [@CR8]; Haradahira et al. [@CR18]; Millan [@CR44]), therefore offering the possibility that ligands acting at this site can modulate the action of glutamate at the NMDA receptor. [d]{.smallcaps}-Cycloserine (DCS) is a partial agonist that acts at the GlycineB site of the NMDA receptor (Hood et al. [@CR23]; Priestley et al. [@CR59]) and is believed to be selective (Millan [@CR44]). As a partial agonist, it acts firstly to bind to the site and prevent the action of glycine (i.e., as an antagonist), but with increasing concentration of the drug, efficacy increases (i.e., an agonist action); at high concentrations, the efficacy of DCS appears to diminish (Priestley et al. [@CR59]). In theory then, if glutamate action at NMDA receptors is involved in the actions of smoking, a single low dose of DCS would reduce effects mediated by a high level of endogenous stimulation at NMDA receptors (via an antagonist action at the GlycineB site) but potentiate its effects where there is a lower level of endogenous activity (via an agonist action at the GlycineB site). We therefore carried out a study to investigate the effects of DCS on the cognitive and subjective effects of smoking. We used 50 mg DCS as a low dose that has previously been reported to be active in human studies (Ressler et al. [@CR63]; Bailey et al. [@CR1]). In addition, to allow the possible bidirectional modulation of smoking effects by DCS, we asked participants to smoke just a portion of a cigarette (partial smoking) following a period of abstinence. We employed a similar battery of tests to those used in our previous study. This included the rapid visual information processing task (RVIP) as a measure of sustained attention, known to be sensitive to the effects of smoking (Wesnes and Warburton [@CR82]) and visual analog scales to measure nicotine- and NMDA-antagonist-related subjective effects (Jackson et al. [@CR25]). In addition, we extended the battery to include a test of attentional set-shifting for two reasons: firstly, we have found in our own studies that smoking can impair performance on the task (Nesic et al. [@CR52]), and secondly, evidence exists to show that glutamatergic ligands, including DCS, can modulate cognitive flexibility in humans (Krystal et al. [@CR32]; Heresco-Levy et al. [@CR19]). To our knowledge, this was the first study to examine the acute effects of DCS in a population of smokers (previously published in abstract form, Nesic et al. [@CR51]).

Method {#Sec2}
======

Participants {#Sec3}
------------

Forty-eight participants (24 male, 24 female) aged 18--34 (mean 22.7 ± SEM 0.6) who smoked 5--20 cigarettes per day (mean 12.5 ± SEM 0.7) were recruited from the staff and students at the Universities of Brighton and Sussex and gave written informed consent to take part in the study. Individuals who habitually smoked more than 20 cigarettes per day were not excluded, but none came forward to take part in the study. The participants were fluent in English, generally healthy, with no previous history of psychiatric illness or substance abuse (verified by a medical check), and were not taking any medication at the time of testing. The volunteers were dependent smokers, as indicated by the Fagerström Tolerance Questionnaire (FTQ; Fagerström [@CR12]) score of 5 or above (5--9, mean 5.8 ± SEM 0.2).

Volunteers were instructed to refrain from smoking for at least 2 h prior to the testing session (actual range 2--34 h, mean 8.6 ± SEM 0.9 h) and were told that compliance would be verified by administration of a Smokerlyzer test. They were asked to avoid using illicit drugs for at least 1 week, sleeping pills and other sedatives for 48 h, and alcohol for 12 h before the testing session. Volunteers were informed that the purpose of the study was to investigate if [d]{.smallcaps}-cycloserine (DCS) is able to modulate the subjective and cognitive effects of smoking. They were told that they would receive a capsule containing either placebo or 50 mg DCS and that they may be asked to smoke a portion of one of their own cigarettes during the testing session. At the start of the testing session volunteers\' IQ was assessed using the National Adult Reading Test (NART).

This study was approved by the Research Ethics Committees of the University of Sussex and the University of Brighton. Participants received £25 at the end of the testing session as compensation for their time.

Experimental design {#Sec4}
-------------------

Volunteers were randomly allocated to one of the four experimental conditions and tested individually in a between-subjects 2 × 2 design, fully balanced for gender, with the between-subjects factors being drug (placebo---PL vs. [d]{.smallcaps}-cycloserine---DCS) and the partial-smoking condition (abstinent---NS vs. partial smoking---S). In order to assess temporal changes during the course of the experimental session, "time point" was introduced as a within-subject factor for some of the dependent variables. Dependent variables were subjective effects, craving for cigarettes, and cardiovascular measures (three time points) as well as sustained attentional performance (one time point).

Drug treatments {#Sec5}
---------------

DCS was obtained from a local pharmacy as generic cycloserine capsules BP (King Pharmaceuticals Ltd, Donegal, Ireland). Drug and placebo (cornstarch) were subsequently prepared in opaque, gelatine-free capsules (Quali-V^®^, Qualicaps) at the School of Pharmacy and Biomolecular Sciences, University of Brighton. A dose of 50 mg DCS was chosen for two reasons: Firstly, this dose has been reported to be active and to have good tolerability in many previous studies (van Berckel et al. [@CR79]; Ressler et al. [@CR63]; Hofmann et al. [@CR22]; Bailey et al. [@CR1]), and secondly, in vitro studies indicate that efficacy is lost at high concentrations (Priestley et al. [@CR59]) and it was unclear at what dose this might occur in vivo.

Demographic questionnaires {#Sec6}
--------------------------

In addition to the FTQ and the questions about the onset and duration of smoking habit, demographic questionnaires included an Alcohol Use Questionnaire (AUQ; Mehrabian and Russell [@CR43]) and the Drug Use Questionnaire (DUQ; Nesic et al. [@CR52]). The AUQ is a self-report questionnaire that establishes the average weekly alcohol intake and patterns of drinking behavior over a 6-month period. The DUQ is a self-report questionnaire that establishes lifetime as well as frequency of current use of illicit drugs, including amphetamines, cocaine, crack, MDMA, hallucinogens, opiates, ketamine, gamma-hydroxy-butyrate (liquid ecstasy), alkyl nitrite inhalants (poppers), nitrous oxide (laughing gas), and cannabis. Drugs included in the DUQ are scored as follows: 0 = never used, 1 = not used in the last month, 2 = used once in the last month, 3 = used 2--5 times in the last month, 4 = used 6--10 times in the last month, 5 = used more than 10 times in the last month (with the exception of cannabis, which is scored as follows: 0 = never smoked, 1 = not smoked in the last month, 2 = smoked once in the last month, 3 = smoked ≤ once a week in the last month, 4 = smoked several times a week in the last month, and 5 = smoked every day in the last month). Analysis is performed on each individual item as well as on the total drug use score which is obtained by adding up all the scores for individual drug items. This is an extended version of a previous DUQ developed in our laboratory which has been used for drug screening purposes in a number of studies involving social drinkers (Nesic and Duka [@CR49]; [@CR50]) and smokers (Nesic et al. [@CR52]).

Subjective measurements {#Sec7}
-----------------------

**Visual analog scales** A list of nicotine-related subjective effects (nicotine-VAS) and a list of NMDA antagonist-related subjective effects (NMDA-VAS) were presented, and volunteers were instructed to answer how much each adjective described how they felt at that moment by placing a mark on the bipolar visual analog scales (VAS---100 mm) with the poles "not at all" on the left and "extremely" on the right. The nicotine-VAS items were "stimulated," "buzzed," "impatient," "alert," "irritable," "jittery," "dizzy," "relaxed," and "hungrier than usual" (Jackson et al. [@CR25]---based on Perkins et al. [@CR58]). The NMDA-VAS items were "lightheaded," "detached," "forgetful," "things seem to be moving in slow motion," and "unreal" (Jackson et al. [@CR25]).

**Questionnaire of Smoking Urges** The brief version of Questionnaire of Smoking Urges (QSU) consists of 10 questions designed to measure desire to smoke and anticipation of positive outcome (factor 1: positive reinforcement) as well as strong urge to smoke and anticipation of relief of withdrawal (factor 2: negative reinforcement; Cox et al. [@CR7]). The participants were required to rate how much each statement applied to them at that particular moment by writing a mark on a Likert-type seven-point scale, ranging from "strongly disagree" (1) to "strongly agree" (7).

Cognitive assessment {#Sec8}
--------------------

**RVIP** A five-minute RVIP test of sustained attention (based on Wesnes and Warburton [@CR82]) was administered using E-Prime 1.1 software and a response box (Psychology Software Tools Inc). Volunteers were required to monitor a continuous stream of digits, presented at a rate of 80 digits per minute, and to press a response button whenever they saw either three consecutive odd or three consecutive even digits. There were eight such target strings of digits in each one-minute block of the 5-min test, making a total of 40 targets. The number of correct targets detections ("hits") was recorded within a 1,500-ms window following the onset of the third digit in the target sequence. The average latency of correct detections and the number of false alarms (responses to nontargets) were also recorded. Due to a technical error, RVIP data were lost for one of the participants in the DCS/S group.

**Intra--extra dimensional set-shift test** The intra--extra dimensional set-shift test (IED; Cambridge Neuropsychological Test Automated Battery, Cambridge Cognition) is a computerized touch-screen test of rule acquisition and reversal, which begins as a simple visual discrimination task and then gradually increases in the degree of complexity. The display features two stimuli in the form of shapes and/or shapes and lines that appear randomly in two of the four possible locations on the computer screen. Initially, volunteers are required to learn a simple discrimination (i.e., which of the two shapes is correct), then simple reversal (i.e., change of contingencies, where the previously incorrect shape becomes correct), and then to attend to the correct shape even when the stimuli become more complex by the addition of the lines. Subsequently, a new pair of the compound shape-line stimuli appears, and volunteers are required to maintain attention to shapes and to ignore the lines (stage 6---the intradimensional (ID) shift). Finally, in stage 8, another new pair of compound stimuli appears, and volunteers are now required to switch their attention to the previously irrelevant dimension, the lines (the extradimensional (ED) shift). The main outcome measures derived from this test are the number of stages completed (1--9), total number of errors on the test, the number of errors made on each of the nine blocks, and the total number of errors prior to the extradimensional shift block. Additionally two composite outcome measures were analyzed: attentional flexibility (errors in stages 6 + 8) and reversal learning (errors in stages 2 + 5 + 7 + 9).

An associative verbal memory test was also used in this study; no effects of DCS or partial smoking were observed on performance of this test, and the results are not reported here.

Experimental procedure {#Sec9}
----------------------

Volunteers reported either to the University of Sussex or to the University of Brighton Psychopharmacology Laboratory having been asked to abstain from smoking for at least 2 h. They first completed a Smokerlyzer test measuring exhaled carbon monoxide (CO) levels in order to verify compliance with the abstinence requirement. At the start of the testing session, volunteers performed the NART after which they were given the opportunity to familiarize themselves with the RVIP task (20--40-s practice trial). Following this, they completed Nic-VAS, NMDA-VAS, and QSU scales (2--3 min), and their blood pressure was measured using an automatic monitor (time point: baseline).

Volunteers were then given a capsule which they swallowed with approximately 100-ml water and waited for 90 min, during which they completed the demographic questionnaires. At the end of the waiting period, participants\' blood pressure was measured again, and they completed a Smokerlyzer test followed by a test battery consisting of a 30-min memory test, Nic-VAS, NMDA-VAS, and QSU (time point: presmoke). After the test battery, half of the volunteers were taken to the designated smoking area and asked to smoke one half of one of their own cigarettes, while the other half of the volunteers remained abstinent. The portion of the cigarette to be smoked was determined individually for each participant by asking them to indicate the point on their cigarette up to which they would normally smoke before putting it out, measuring the length of this portion and then marking a line halfway along to ensure that they smoked exactly one half of the amount that they would usually smoke. Upon returning to the testing room, participants completed another Smokerlyzer test followed by a test battery consisting of nicotine-VAS, NMDA-VAS, QSU, RVIP, IED, and a 10-min memory test, after which their blood pressure was measured again (time point: postsmoke). At the end of testing, participants were debriefed about the purpose of the study, were given £25, and were allowed to leave the laboratory.

Data analyses {#Sec10}
-------------

Demographic data, duration of abstinence, baseline breath CO, and NART scores of the four experimental groups were analyzed using univariate analysis of variance (ANOVA) with drug group (PL vs. DCS) and partial-smoking condition (NS vs. S) as between-subjects factors. The effects of the drug alone on subjective measures were evaluated using repeated-measures ANOVA with drug group as the between-subjects factor and time point (baseline vs. presmoking) as the within-subjects factor.

Prior to analyzing the effects of the drug and the partial-smoking manipulation on subjective measures and breath CO levels, data from the presmoking time point were analyzed using univariate ANOVAs with drug group and partial-smoking condition as between-subjects\' factors. Whenever there was a significant interaction of the two factors at this time point, the postsmoking data for that variable were converted into percent of change from the presmoking time point and analyzed using univariate ANOVA with drug and partial-smoking group as between-subjects\' factors. If the interaction of the two factors at the presmoking time point was not significant, these variables were evaluated using repeated-measures ANOVA with the drug group and the partial-smoking condition as between-subject factors and time point (pre- vs. postsmoking) as a within-subject factor. Since the distribution of response latencies on the RVIP usually shows positive skewness, natural log transformation was applied to normalize these data prior to analyses. RVIP data (response latencies, hits, false alarms) as well as IED outcome measures were analyzed using univariate ANOVA, with drug group and partial-smoking condition as between-subject factors.

All significant interactions were explored using appropriate paired and/or unpaired post hoc *t* tests. We have decided against applying corrections for multiple comparisons as this was a simple 2 × 2 design (2 × 2 × 2 for the subjective effect variables which were measured before and after the drug and/or smoking manipulation), and such corrections are not recommended for exploration of significant interactions which involves five or less planned post hoc comparisons (Roberts and Russo [@CR68]).

All statistical analyses were performed using SPSS 15.0.

Results {#Sec11}
=======

Population characteristics {#Sec12}
--------------------------

The four experimental groups were matched with respect to age, NART, and smoking habit as well as alcohol and other drug use (*F*s\[1,44\] \< 3.60, *p*s \> 0.06). Demographic characteristics of the four groups are presented in Table [1](#Tab1){ref-type="table"}. A main effect of drug group was significant for the number of hours since the last cigarette, with volunteers allocated to the DCS group being abstinent for longer than those in the PL group (means ± SEM: PL = 6.7 ± 1.0 h, DCS = 10.5 ± 1.5 h; *F*\[1,44\] = 4.62, *p* \< 0.05). Furthermore, a significant main effect of the smoking group was observed for the baseline breath CO levels, with participants allocated to the nonsmoking condition having higher baseline levels (*F*\[1,44\] = 4.79, *p* \< 0.05; Table [2](#Tab2){ref-type="table"}). In order to control for the potentially confounding influence of these differences on the experimental outcome measures, the number of hours since last cigarette was entered as a covariate in all subsequent ANOVAs, while the baseline breath CO level was entered as an additional covariate only in the analyses of the postsmoking time point measurements. Only results from the ANCOVAs will be reported here. Table 1Demographic characteristics of the four experimental groups (DCS = [d]{.smallcaps}-cycloserine condition, PL = placebo condition, S = partial-smoking condition, NS = nonsmoking condition)*n* = 12 per group (6 male, 6 female)DCS/NSDCS/SPL/NSPL/SAge (years)24.3 (1.5)22.4 (1.0)22.5 (1.2)21.6 (0.8)NART score33.0 (2.5)28.9 (1.7)29.0 (2.1)30.0 (1.3)Number of cigarettes/day12.4 (1.7)11.7 (1.4)12.1 (1.1)13.8 (1.8)FTQ score5.9 (0.4)5.3 (0.2)5.8 (0.2)6.1 (0.4)Number of years smoking regularly8.5 (1.7)6.3 (0.9)6.7 (1.0)5.7 (0.9)Alcohol use (units/week)37.2 (6.6)38.0 (7.5)27.5 (3.9)30.0 (4.4)Drug use (total DUQ score)8.8 (1.8)9.6 (1.9)6.4 (1.2)6.6 (1.7)Values represent means (±SEM)Table 2CO, blood pressure and heart rate of the four experimental groups (DCS = [d]{.smallcaps}-cycloserine condition, PL = placebo condition, S = partial-smoking condition, NS = nonsmoking condition) at predrug baseline (t1), before (t2), and after the partial-smoking manipulation (t3)Breath CO (ppm)Systolic BP (mmHg)Diastolic BP (mmHg)Heart rate (beats/min)t1^§§^t2^\#\#\#^t3\*\*\*t1t2t3\*\*t1^†^t2^†††^t3t1t2t3DCS/NS8.3 (1.8)6.9 (1.6)6.0 (1.4)112.0 (3.9)113.3 (3.2)109.7 (3.3)67.7 (3.2)63.9 (2.5)65.8 (2.7)74.6 (4.0)65.0 (3.1)65.4 (3.6)DCS/S5.3 (1.0)4.8 (0.9)5.8 (0.9)115.1 (2.5)111.9 (2.5)114.0 (3.3)67.8 (2.6)64.4 (2.2)71.1 (2.6) ‡65.7 (1.9)62.8 (3.1)65.8 (3.2)PL/NS10.5 (1.9)8.0 (1.5)6.6 (1.2)123.5 (3.9)118.5 (3.5)117.5 (3.4)75.2 (1.8)70.6 (1.4)73.3 (2.0)74.8 (4.0)67.8 (3.9)63.0 (2.2)PL/S4.9 (1.0)4.2 (0.9)5.8 (0.9)118.1 (4.8)114.8 (3.9)121.2 (3.0)71.2 (2.2)73.8 (2.6)72.1 (1.8)73.1 (3.6)72.3 (2.3)72.0 (3.4)The four groups underwent identical protocol until the partial-smoking manipulation, which occurred after t2. Values represent means (±SEM)^§§^*p* \< 0.01 (main effect of smoking group; S \< NS); ^\#\#\#^  *p* \<0.001 (main effect of time point; t2 vs. t1); \*\**p* \< 0.01; \*\*\**p* \< 0.001 (smoking group × time point interaction; S: t2 \< t3, N: t2 ≥ t3); ^†^*p* \< 0.05; ^†††^*p* \< 0.001 (main effect of drug group; DCS \< PL); ^‡^*p* \< 0.05 (time × drug group × smoking group interaction; t3 \> t2 in the DCS/S group)

Physiological effects {#Sec13}
---------------------

### Effects of DCS during abstinence (baseline vs. presmoke) {#Sec14}

The ANCOVA of breath CO levels during abstinence (baseline vs. presmoking) revealed a main effect of time, with all participants showing a decline in CO levels across the two time points (*F*\[1,45\] = 53.69, *p* \< 0.001; Table [2](#Tab2){ref-type="table"}).

Blood pressure and heart rate remained constant during abstinence (main effects of time: *F*s\[1,45\] \< 2.50, n.s.). DCS did not exert any significant effects on either systolic or diastolic blood pressure (time × drug interaction: *F*s\[1,45\] \< 0.84, n.s.), although a main effect of drug was found for the diastolic blood pressure (*F*\[1,45\] = 9.71, *p* \< 0.005; Table [2](#Tab2){ref-type="table"}). Post hoc independent *t* tests indicated that the participants in the DCS group had lower diastolic blood pressure than the PL group at baseline as well as at the presmoking measurement point (*t*\[46\] = 2.19, *p* \< 0.05 and *t*\[46\] = 3.66, *p* \< 0.001, respectively). No other main effects or interactions were observed for the blood pressure and heart rate data (*F*s\[1,45\] \< 2.85, n.s.). Blood pressure and heart rate data are presented in Table [2](#Tab2){ref-type="table"}.

### Effects of DCS in combination with partial smoking (presmoke vs. postsmoke) {#Sec15}

Repeated ANCOVA of the CO levels before and after the partial-smoking manipulation in the entire experimental sample revealed a significant two-way interaction of partial-smoking condition and time point (*F*\[1,42\] = 34.50, *p* \< 0.001; Table [2](#Tab2){ref-type="table"}). Post hoc *t* tests revealed that breath CO significantly increased in the S condition (*t*\[23\] = −5.27, *p* \< 0.001) and declined in the NS condition (*t*\[23\] = 4.61, *p* \< 0.001). The three-way interaction of drug group, partial-smoking manipulation, and time point was not significant (*F*\[1,42\] = 1.80, n.s.) suggesting that DCS did not alter the amount of smoke inhaled.

A significant three-way interaction for the diastolic blood pressure was revealed in the repeated ANCOVA (time × drug × smoking: *F*\[1,42\] = 7.56, *p* \< 0.01; Table [2](#Tab2){ref-type="table"}). Post hoc *t* tests indicated that partial smoking significantly increased diastolic blood pressure only in the DCS group (*t*\[11\] = −3.01, *p* \< 0.05), while a similar increase was not observed in the PL group (*t*\[11\] = 0.82, n.s.). The main effect of drug was again significant (*F*\[1,42\] = 9.51, *p* \< 0.01), although the DCS group no longer had lower blood pressure than the PL group at the postsmoking measurement (independent *t*\[41.14\] = 1.80, n.s.). Independently of the drug manipulation, partial smoking also induced a significant increase in systolic blood pressure (*t*\[23\] = −2.51, *p* \< 0.05) which was not seen in the abstinent group (*t*\[23\] = 1.288, n.s.; smoking × time point interaction: *F*\[1,42\] = 9.81, *p* \< 0.005; Table [2](#Tab2){ref-type="table"}). No other main effects or interactions were observed in the analyses of the blood pressure and heart rate (*F*s\[1,42\] \< 2.65, n.s.).

Subjective effects {#Sec16}
------------------

### Effects of DCS during abstinence (baseline vs. presmoke) {#Sec17}

Main effects of time point were observed for Nic-VAS ratings "buzzed," "impatient," "dizzy," "relaxed," and "hungrier than usual" and NMDA-VAS ratings of "detached," "slow motion," and "unreal" (*F*s\[1,45\] \> 4.35, *p*s \< 0.05; Table [3](#Tab3){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). All ratings increased significantly between baseline and presmoking measurements (paired *t*s\[47\] \< −2.716, *p*s \< 0.01), apart from the "relaxed" ratings, which tended to decrease (paired *t*\[47\] = 3.30, *p* \< 0.005). In addition, a significant main effect of time point was observed for the QSU factor 2 (*F*\[1,45\] = 7.54, *p* \< 0.01; Table [4](#Tab4){ref-type="table"}), indicating that the negative reinforcement aspect of craving significantly increased across the two time points in all participants (paired *t*\[47\] = −4.18, *p* \< 0.001). Table 3Effects of [d]{.smallcaps}-cycloserine (DCS) and placebo (PL) on subjective ratings (nicotine-VAS and NMDA-VAS items) during nicotine abstinence*df* = 1, 45DCSPLt1t2t1t2Nicotine-VAS"Buzzed"^\#^19.3 (4.1)34.1 (6.3)22.6 (4.0)30.6 (5.3)"Impatient"^\#^27.1 (5.1)40.7 (5.5)30.3 (4.4)46.5 (4.8)"Alert"44.0 (5.1)46.1 (5.5)46.2 (4.6)50.0 (4.5)"Irritable"24.5 (4.9)27.1 (5.3)31.2 (4.6)42.0 (5.6)"Jittery"21.6 (4.8)25.5 (5.5)29.8 (4.4)34.5 (4.9)"Dizzy"^\#^17.0 (4.3)22.5 (5.4)17.5 (3.8)31.2 (5.1)"Hungrier than usual"^\#^31.2 (6.4)38.3 (6.5)30.8 (5.9)49.3 (6.7)NMDA-VAS"Lightheaded"26.4 (5.7)35.9 (6.0)30.0 (4.8)40.0 (4.9)"Detached"^\#^27.3 (4.7)37.6 (5.5)30.7 (4.8)43.3 (5.2)"Forgetful"32.5 (4.5)42.4 (5.6)38.9 (4.9)38.7 (5.6)"Slow motion"^\#\#^16.5 (4.5)23.5 (5.7)16.3 (3.2)26.9 (5.5)"Unreal"^\#^16.1 (4.6)21.4 (5.3)16.3 (3.8)23.5 (4.9)Measurements were taken at predrug baseline (t1), and 90 min after drug (t2). Values represent means (±SEM)^\#^*p* \< 0.05; ^\#\#^*p* \< 0.01 (main effect of time point; t2 vs. t1)Fig. 1Effects of drug (*DCS*) or placebo (*PL*) on Nic-VAS ratings of **a** "Stimulated" and **b** "Relaxed" at predrug baseline (*t1*), presmoking (*t2*), and postsmoking measurement point (*t3*). *NS* nonsmoking group, *S* partial-smoking group (the two groups underwent identical protocol until the partial-smoking manipulation which occurred after t2). ‡*p* \< 0.05, ‡‡*p* \< 0.01 (t1 vs. t2; paired *t* test within DCS group), \**p* \< 0.05 (t2 vs. t3; paired *t* test within PL-S and DCS-S groups)Table 4QSU ratings of the two smoking groups (S = partial-smoking condition, NS = nonsmoking condition) at predrug baseline (t1), before (t2), and after the partial-smoking manipulation (t3)QSU factor 1---positive reinforcementQSU factor 2---negative reinforcementt1t2t3\*\*\*t1t2^\#\#^t3\*\*DCS/NS5.3 (0.4)5.7 (0.4)5.6 (0.4)3.2 (0.5)3.9 (0.6)3.6 (0.6)DCS/S5.5 (0.3)5.4 (0.4)4.1 (0.4)2.8 (0.2)2.9 (0.4)2.0 (0.3)PL/NS5.3 (0.4)5.6 (0.4)5.7 (0.4)2.6 (0.3)2.8 (0.3)3.1 (0.5)PL/S5.2 (0.5)5.6 (0.5)3.6 (0.5)3.4 (0.4)4.3 (0.5)2.7 (0.3)The two groups underwent identical protocol until the partial-smoking manipulation, which occurred after t2. Values represent means (±SEM), minimum score 1, maximum 7\*\*\**p* \< 0.001 (smoking group × time point interaction; S: t2 \< t3, N: t2 = t3); \*\**p* \< 0.01 (main effect of smoking group on the t3 scores expressed as % change from t2); ^\#\#^*p* \< 0.01 (main effect of time point; t2 vs. t1)

ANCOVA revealed a significant interaction of drug and time point for the Nic-VAS "stimulated" ratings (F\[1,45\] = 5.82, *p* \< 0.05). Ratings for "stimulated" increased across time in the DCS group (paired *t*\[23\] = −2.823, *p* \< 0.01), while this was not observed in the PL group (*t*\[23\] = 0.36, n.s.; Fig. [1a](#Fig1){ref-type="fig"}). All other subjective measures remained unaltered by DCS (drug × time interaction *F*s\[1,45\] \< 1.78, n.s.).

### Effects of DCS in combination with partial smoking (presmoke vs. postsmoke) {#Sec18}

Univariate ANCOVA of percent change from the presmoking time point was deemed necessary for Nic-VAS "buzzed," "jittery," and "dizzy" ratings, NMDA-VAS "lightheaded," "detached," and "slow motion," and QSU factor 2, since the analyses of the presmoking time point ratings for these dependent variables indicated a drug × condition interaction (*F*s\[1,42\] \> 4.36, *p*s \< 0.05).

A significant interaction of drug group, partial-smoking condition, and time point was observed for the Nic-VAS "stimulated" and "relaxed" ratings (respectively, *F*\[1,42\] = 7.50, *p* \< 0.01 and *F*\[1,42\] = 5.18, *p* \< 0.05). Partial smoking induced an increase in "stimulated" and "relaxed" feelings in the PL group (respectively, paired *t*\[11\] = −2.45, *p* \< 0.05 and *t*\[11\] = −2.48, *p* \< 0.05). In contrast, in the group given DCS, ratings for "stimulated" decreased significantly (*t*\[11\] = 2.44, *p* \< 0.05; Figure [1a](#Fig1){ref-type="fig"}), whereas ratings for "relaxed" remained the same after partial smoking compared with the presmoking time point (*t*\[11\] = −0.27, n.s.; Figure [1b](#Fig1){ref-type="fig"}).

In both treatment groups, partial smoking induced an increase in Nic-VAS "buzzed" ratings (% change from presmoking time point, means ± SEM: S = 175.87 ± 55.28%, NS = 16.17 ± 21.43%; main effect of smoking *F*\[1,42\] = 4.32, *p* \< 0.05) and a decrease in QSU factor 2 scores (% change from presmoking time point; main effect of smoking *F*\[1,42\] = 8.16, *p* \< 0.01; see Table [4](#Tab4){ref-type="table"}). In addition, a significant interaction of smoking group and time point was observed in the ANCOVA of QSU factor 1 scores (*F*\[1,42\] = 15.90, *p* \< 0.001; Table [4](#Tab4){ref-type="table"}), and post hoc tests revealed that the scores declined after partial smoking (*t*\[23\] = 5.06, *p* \< 0.001) while they tended to remain unchanged in the nonsmoking group (*t*\[23\] = −0.35, n.s.). DCS did not modulate the effects of partial smoking either on the QSU ratings or on the subjective ratings of "buzzed" (main effect and interaction *F*s\[1,42\] \< 1.93, n.s.).

Cognitive effects {#Sec19}
-----------------

### Effects of DCS in combination with partial smoking (postsmoke measurement point) {#Sec20}

Neither partial smoking nor drug treatment altered the number of hits occurring during the RVIP test (means ± SEM: DCS/NS = 22.8 ± 2.5, DCS/S = 25.9 ± 2.2, PL/NS = 27.3 ± 2.5, PL/S = 23.4 ± 2.6; main effects and interaction *F*s \[1,42\] \< 0.91, n.s.). However, a significant interaction of drug and partial-smoking condition was revealed for the number of false alarms (*F*\[1,41\] = 4.49, *p* \< 0.05; Figure [2a](#Fig2){ref-type="fig"}). Partial smoking reduced the number of false alarms in the DCS group participants, who made significantly less errors than their nonsmoking counterparts (*t*\[12.91\] = 2.32, *p* \< 0.05) as well as less errors than the PL group participants who smoked (*t*\[12.29\] = 2.17, *p* = 0.05). In addition, a significant main effect of drug group was observed for response latencies (*F*\[1,41\] = 6.43, *p* \< 0.05; Fig. [2b](#Fig2){ref-type="fig"}) reflecting the tendency for the participants in the DCS group to have longer latencies than those in the PL group (*t*\[45\] = −3.04, *p* \< 0.005). Partial smoking alone or in combination with DCS failed to exert a significant effect on response latencies (main effect and interaction *F*s\[1,41\] \< 2.95, n.s.). Fig. 2**a** Number of false alarms and **b** mean response times (*log*) on the rapid visual information processing (*RVIP*) test following partial smoking (*S*) or the nonsmoking (*NS*) manipulations in participants who underwent the drug (*DCS*) or the placebo (*PL*) treatment. \**p* ≤ 0.05 (independent *t* test vs. DCS-S groups), †*p* \< 0.05 (main effect of drug group PL vs. DCS)

None of the aspects of IED test performance appeared to be influenced either by drug treatment or by partial smoking (main effects and interactions: *F*s\[1,42\] \< 3.06, *p*s \> 0.08) apart from the number of errors made in the first two reversal blocks which tended to be reduced in the partial smoking compared to the abstinent condition (main effect of smoking condition; Block 2 errors: *F*\[1,42\] = 4.23, *p* \< 0.05; Block 5 errors: *F*\[1,42\] = 4.02, *p* = 0.052; Table [5](#Tab5){ref-type="table"}). A nonsignificant trend for partial smoking to improve IED performance was also observed in the analysis of total number of errors prior to the extradimensional shift block (main effect of smoking condition on Blocks 1--7; *F*\[1,42\] = 2.98, *p* = 0.053). However, the analysis of this variable also revealed that duration of abstinence was a significant determinant of test performance (*F*\[1,42\] = 12.38, *p* \< 0.001), and post hoc correlational analysis indicated that longer abstinence was related to greater number of errors prior to the extradimensional shift (Pearson\'s *r* = 0.40, *p* \< 0.005). Table 5IED test performance of the four experimental groups (DCS = [d]{.smallcaps}-cycloserine condition, PL = placebo condition, S = partial-smoking condition, NS = nonsmoking condition)*n =* 12 per group (6 male, 6 female)DCS/NSDCS/SPL/NSPL/SNumber of stages completed8.5 (0.3)9.0 (0.0)8.7 (0.2)8.8 (0.2)Total number of errors (adjusted for the stages not completed)24.6 (6.3)12.4 (2.2)20.6 (4.7)17.3 (4.2)Number of errors in stage 1 (discrimination learning)0.2 (0.1)0.4 (0.1)0.5 (0.2)0.7 (0.3)Number of errors in stage 2 (simple reversal learning)\*1.7 (0.2)1.3 (0.1)1.5 (0.3)1.2 (0.1)Number of errors in stage 3 (new dimension introduced but ignored)2.3 (1.8)1.2 (0.2)2.7 (1.0)1.0 (0.2)Number of errors in stage 4 (new dimension still ignored)0.3 (0.1)0.6 (0.3)0.2 (0.1)0.1 (0.1)Number of errors in stage 5 (reversal, still ignoring the new dimension)^\#^1.5 (0.2)1.0 (0.0)1.4 (0.2)1.3 (0.2)Number of errors in stage 6 (intradimensional set-shift)0.6 (0.1)0.5 (0.2)0.8 (0.2)0.8 (0.2)Number of errors in stage 7 (reversal, still ignoring the new dimension)1.3 (0.2)1.1 (0.1)1.4 (0.3)1.2 (0.1)Number of errors in stage 8 (extradimensional set-shift)9.5 (3.3)4.9 (2.4)6.2 (2.4)7.3 (2.6)Number of errors in stage 9 (reversal, still attending to the new dimension)1.3 (0.2)^†††^1.5 (0.3)2.1 (0.8)^††^1.8 (0.2)^†^Total number of errors prior to extradimensional set-shift (blocks 1--7)^\#^7.8 (2.0)6.0 (0.6)8.5 (1.1)6.2 (0.5)Reversal learning (errors in stages 2 + 5 + 7 + 9)5.4 (0.6)^†††^4.8 (0.3)6.5 (0.9)^††^5.5 (0.4)^†^Attentional flexibility (errors in stages 6 + 8)10.1 (3.3)5.4 (2.3)7.0 (2.4)8.2 (2.6)Test was performed after the smoking manipulation. Values represent means (±SEM)^†^*n* = 11, ^††^*n* = 10, ^†††^*n* = 9\**p* \< 0.05; ^\#^*p* \< 0.055 (main effect of smoking group)

Discussion {#Sec21}
==========

The main findings from this study were that DCS, a partial agonist at the GlycineB site of the NMDA receptor, given alone had a mild stimulant effect in abstinent smokers and slowed reaction times somewhat, during a task of sustained attention. It reduced the subjective stimulant effect of partially smoking a cigarette and the accompanying increase in relaxation. In addition, DCS interacted with the effect of partial smoking to produce a small increase in blood pressure. While there was no interaction between DCS and partial smoking on attentional accuracy, there was an improvement in inhibitory control. These results fit well with those of our previous study using the NMDA antagonist memantine (Jackson et al. [@CR25]) and which suggested a role for glutamate in subjective response to smoking, but not in the effects on attentional accuracy. Our current study also extends those results to reveal the role of glutamate in inhibitory control.

At the dose of 50 mg DCS used in this study, we expected to see either "agonist-like" interactions or "antagonist-like" interactions with smoking (see "[Introduction](#Sec1){ref-type="sec"}" section). A mild stimulant effect was detected using the Nic-VAS rating scales. Previous studies using this dose of DCS have not detected this subjective response in healthy volunteers (van Berckel et al. [@CR79]; D'Souza et al. [@CR10]; Bailey et al. [@CR1]), although this is the first study to focus on a population of smokers. It seems unlikely that this reflects the antagonist property of DCS, as no effects were detected on the NMDA-VAS rating scales, which we have previously shown to be sensitive to the effects of the NMDA antagonist memantine (Jackson et al. [@CR25]). It is more likely that the stimulant action represents an agonist property of DCS, and accordingly, this would imply that glutamate action at NMDA receptors is relatively low in smokers during early abstinence. Preclinical studies indicate that although the subjective effects of nicotine are partly mediated by the mesolimbic system, the primary site of action may be in the prefrontal cortex (Miyata et al. [@CR45]; Smith and Stolerman [@CR77]). Interestingly, NMDA receptors containing NR2B subunits, for which DCS has preferential affinity (Priestley et al. [@CR59]), upregulate in the PFC as a consequence of chronic nicotine self-administration (Wang et al. [@CR80]). Such an upregulation could account for the stimulant-like effects of DCS seen in abstinent smokers in this study, an effect not seen in other studies employing healthy volunteers.

In addition to its effect on stimulant ratings per se during abstinence, DCS also interacted with the subjective effects of partial smoking to reduce the increases seen in relaxed and stimulant ratings. This effect parallels results seen with NMDA antagonists in preclinical studies investigating the stimulus properties of nicotine (Zakharova et al. [@CR84]; Murray and Bevins, [@CR48]). The result is also consistent with our previous results showing modulation of smoking-induced subjective response using the Nic-VAS rating scales, although the modulated effects differed in that previously we found evidence for changes in ratings for "buzzed" (Jackson et al. [@CR25]). One reason for this difference may be that in the current study, participants were asked to smoke only a portion of a cigarette, whereas previously, they smoked a whole cigarette, thus differential self-dosing produced a different profile of subjective effects. Different self-dosing is supported by comparison of the pre--postsmoking change in CO levels of the two studies (an average increase of 141.1% vs. 43.6% in the current study). Nevertheless, both studies provide evidence to support a role for glutamate release underlying subjective response to smoking. In addition, the "bidirectional action" of DCS on stimulant ratings depending on whether participants smoked or were abstinent fits well with the predicted action of DCS varying according to different levels of endogenous glutamate activity.

In contrast to the results obtained using the Nic-VAS rating scales, DCS did not alter craving measured by the QSU. Both factor 1 craving (positive reinforcement) and factor 2 craving (negative reinforcement) were reduced following the partial-smoking manipulation; DCS neither potentiated nor prevented this effect. Again, these results are consistent with those of our previous study with memantine (Jackson et al. [@CR25]) and suggest that mechanisms other than glutamate activity at NMDA receptors may be involved in abstinence-related craving. Interestingly, our results differ from those of Santa Ana et al. ([@CR73]) where following repeated dosing with DCS, cue-induced (conditioned) craving was attenuated.

DCS lacked any effect on physiological measures, either alone or in combination with partial smoking, with one exception. While neither DCS alone nor smoking alone altered blood pressure, when in combination, a small increase in diastolic blood pressure was seen. Pressor responses seen after central administration of nicotinic agonists have been pharmacologically characterized and indicate that they are mediated via α7 homomeric nicotinic receptors (Brezenoff and Giuliano [@CR4]; Buccafusco and Yang [@CR5]; Li and Buccafusco [@CR36]). As stimulation of α7 homomeric receptors can modulate glutamate release in several different areas of the brain (Kaiser and Wonnacott [@CR28]; Schilstrom et al. [@CR75]; Jones and Wonnacott [@CR27]; Livingstone et al. [@CR37]), a reasonable interpretation of our results is therefore that the increase in diastolic blood pressure seen following combined DCS and partial smoking was related to the agonist action of DCS potentiating the action of glutamate at central NMDA receptors. A candidate area in the brain for this action of DCS is the ventral portion of the medial prefrontal cortex---firstly because the prefrontal cortex contains both α7 nicotinic receptors (Paterson and Nordberg [@CR55]) and NMDA receptors containing NR2B subunits (Laurie et al. [@CR33]; Loftis and Janowsky [@CR38]), and secondly, there is evidence for the involvement of glutamate in ventromedial prefrontal cortex provoked increases in blood pressure in unanesthetized rats (Resstel and Correa [@CR64]).

DCS had no effect on the number of "hits" (target detections) achieved during performance of the RVIP test, either alone or in combination with partial smoking. Partial smoking itself did not improve performance, although this might have been expected given the well-established effect of nicotine in this test (Wesnes and Warburton [@CR82]). This lack of effect, however, is likely to stem from the fact that smoking half of the usual amount of tobacco is insufficient to produce the beneficial effect on attention. Indeed, Rezvani et al. ([@CR65]) observed that low doses of nicotine did not affect the number of "hits" in a visual signal detection test in rats even though they increased percent of correct rejections. However, under these conditions of low nicotine dosage, a beneficial effect of DCS in combination with partial smoking on the number of hits would likely have been detected, if this particular effect of smoking on sustained attention involves glutamate activity at NMDA receptors. There is some discrepancy with the preclinical literature in that one study investigating the beneficial action of nicotine in a 5-CSRTT found that the NMDA antagonist CPP was able to reduce the effect of nicotine on attentional accuracy (Quarta et al. [@CR60]). It is possible then that had partial smoking improved attentional accuracy in our participants that DCS might have attenuated such an effect. However, our interpretation that glutamate action at NMDA receptors does not play a major role in this effect of smoking fits well with two other lines of evidence. Firstly, preclinical studies employing selective nicotinic ligands suggest that increases in attentional performance are primarily mediated by non-α7 receptor subtypes (Blondel et al. [@CR3]; Grottick and Higgins [@CR17]). Secondly, we previously found that the enhanced attentional accuracy in the RVIP test following smoking a whole cigarette was prevented by a low dose of mecamylamine but not by memantine (see Jackson et al. [@CR25] and discussion therein). Overall then, our results confirm that mechanisms underlying the positive attentional effects of smoking probably do not involve actions at NMDA receptors. There was some evidence that DCS slowed performance overall, during the task of sustained attention, as reaction times were increased. This effect however was independent of the partial-smoking manipulation. While this might suggest that DCS can affect response times, the lack of specific interaction makes it difficult to interpret in terms of a role for glutamate in the effects of smoking on speed of processing.

In contrast to the lack of specific effects on other measures of RVIP performance, DCS interacted with the partial-smoking manipulation to improve inhibitory control, as measured by the number of errors on the task. This result is in line with the observation that low doses of nicotine dose-dependently increase the percentage of correct rejections in a visual signal detection test in rats without affecting the number of hits (Rezvani et al. [@CR65]). It is unlikely that the reduction in errors was secondary to slower reaction times as this effect only occurred when partial smoking and DCS were combined. In addition, the reduced error rate dissociated from target detection rate, which did not vary across the experimental conditions. Recently, it has been suggested that lapses in attention may contribute toward drug dependence via mechanisms that are independent of those involved in inhibitory control over behavior (De Wit, [@CR9]). The results reported here are consistent with such a suggestion, at least in terms of a role for glutamate in tobacco dependence.

It is of interest to note here the wealth of evidence for the role of glutamate in inhibitory control. Administration of glutamate receptor antagonists such as phencyclidine, dizocilpine, or ketamine induces impulsive or premature responding for food rewards in rats (Sanger and Jackson [@CR72]; Sanger [@CR71]; Higgins et al. [@CR20]) and primates (Jentsch et al. [@CR26]) or impairs the inhibition of inappropriate responses during performance of cognitive tests in humans (Krystal et al. [@CR32]; [@CR31]; Morgan et al. [@CR46]). Furthermore, NMDA antagonists that are selective for receptors containing the NR2B subunit (traxoprodil, Ro 63-1908) also increase premature responding in animal studies (Higgins et al. [@CR20]; [@CR21]). Finally, Murphy et al. ([@CR47]) showed that infusions of the competitive NMDA receptor antagonist CPP, into infralimbic (but not prelimbic) cortex increased premature responding in rats performing a 5-CSRTT (this measure may be a parallel of RVIP error rate) and have consequently suggested that glutamatergic systems involved in response inhibition are localized to a ventromedial area of prefrontal cortex. In the light of a great deal of evidence indicating that antagonists at NMDA receptors impair inhibitory control, it is reasonable to conclude that the effect of DCS in combination with partial smoking reflects an agonist action, that is, a potentiation of the effect of glutamate, possibly mediated in the ventromedial prefrontal cortex.

There was no evidence that partial smoking affected performance on the attentional set-shifting task other than by reducing the number of reversal errors. Although we have previously seen smoking-induced impairment in the intradimensional set shift component of this task (Nesic et al. [@CR52]), those results were obtained after smoking a whole cigarette, so it is probable that the lack of effect in the present study was due to the self-administration of a subthreshold dose of nicotine. Set shifting was also unaltered by DCS alone, or the combination with partial smoking. So, while ligands acting at NMDA receptors have been shown to alter perseverative responding in tests of cognitive flexibility in other populations (Krystal et al. [@CR32]; Heresco-Levy et al. [@CR19]), we were unable to detect an effect of DCS in smokers, nor did we see any potentiation of partial smoking. Given the ability of DCS to potentiate the effects of limited smoking on other measures (blood pressure, inhibitory control), this once again emphasizes the dissociation in mechanisms underlying the different cognitive actions of nicotine.

An important issue, which complicates the interpretation of the present findings, is the baseline difference in the duration of smoking abstinence between the two drug groups. Analysis of covariance was used to try to control for this confounding effect as well as for the confounding effect of the differential level of breath CO at baseline (reflecting abstinence duration as well as the habitual level of smoking) in the two smoking groups, but this may not have been sufficient. This issue is also pertinent considering that the state of glutamatergic transmission may vary depending on the degree of dependence and the duration of smoking deprivation (see Markou [@CR40] for a review), and thus the effects of DCS and/or partial smoking may differ between individuals in early, compared to those in more advanced, nicotine withdrawal. Furthermore, as the mode of action of DCS depends on the dose (Priestley et al. [@CR59]) as well as on endogenous glutamatergic tone (Jackson [@CR24]), a study, which would systematically vary the doses of DCS as well as of nicotine, while controlling for the duration of abstinence, is needed to produce dose--response data which would give more detailed insight into the involvement of NMDA receptor activation in the subjective and cognitive effects of smoking. Another problem with the present study is the relatively small sample size. Although the sample of 12 per group was selected because it has relatively high power (0.80) to detect medium-sized effects (α = 0.25), the inclusion of the covariates in the analyses has reduced this power. Future studies with a larger number of participants are needed to confirm the significance of the present findings.

In summary, the glycine-site partial agonist DCS had bidirectional effects on subjective ratings in moderately dependent smokers, depending on whether they were abstinent or had partially smoked a cigarette. In combination with partial smoking, DCS produced a small increase in blood pressure and improved inhibitory control, but did not affect attentional accuracy or set shifting. These results are consistent with a role for glutamate in the some of the subjective and physiological effects of smoking and with a dissociation in mechanisms underlying the cognitive actions. Considered in the context of current knowledge about relevant brain mechanisms, our results point to the actions of DCS being mediated in the ventromedial prefrontal cortex.
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